Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
52.9M
-
Shares change
-
+5.21M
-
Total reported value, excl. options
-
$567M
-
Value change
-
+$55.4M
-
Number of buys
-
59
-
Number of sells
-
-29
-
Price
-
$10.73
Significant Holders of Cytek Biosciences, Inc. - Common Stock (CTKB) as of Q2 2022
93 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock as of Q2 2022.
Cytek Biosciences, Inc. - Common Stock (CTKB) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.9M shares
of 127M outstanding shares and own 41.74% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (13.4M shares), HHLR ADVISORS, LTD. (8.76M shares), BlackRock Inc. (7.14M shares), VANGUARD GROUP INC (6.27M shares), Blue Water Life Science Advisors, LP (2.1M shares), STATE STREET CORP (1.73M shares), Miura Global Management, LLC (1.65M shares), Point72 Asset Management, L.P. (1.54M shares), GEODE CAPITAL MANAGEMENT, LLC (1.15M shares), and RTW INVESTMENTS, LP (917K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.